On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapythrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] Study)

American Journal of Cardiology

Volumn 106, Issue 4, 2010, Pages 451-456

  Khera, Amit V ^a   Wolfe, Megan L ^a   Cannon, Christopher P ^b   Qin, Jie ^b   Rader, Daniel J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; C REACTIVE PROTEIN; HEPTANOIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ACUTE CORONARY SYNDROME; BLOOD; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

ACUTE CORONARY SYNDROME; C-REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRAVASTATIN; PROPORTIONAL HAZARDS MODELS; PYRROLES; RECURRENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 77955459494     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.03.057     Document Type: Article

References (27)

1. A. Tall Plasma cholesteryl ester transfer protein J Lipid Res 34 1993 1255 1274
2. M.E. Brousseau, E.J. Schaefer, M.L. Wolfe, L.T. Bloedon, A.G. Digenio, R.W. Clark, J.P. Mancuso, and D.J. Rader Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515
3. P.J. Barter, M. Caulfield, M. Eriksson, S.M. Grundy, J.J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J.C. Tardif, D.D. Waters, C.L. Shear, J.H. Revkin, K.A. Buhr, M.R. Fisher, A.R. Tall, B. Brewer ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
4. S.E. Nissen, J.C. Tardif, S.J. Nicholls, J.H. Revkin, C.L. Shear, W.T. Duggan, W. Ruzyllo, W.B. Bachinsky, G.P. Lasala, E.M. Tuzcu ILLUSTRATE Investigators Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
5. J.J. Kastelein, S.I. van Leuven, L. Burgess, G.W. Evans, J.A. Kuivenhoven, P.J. Barter, J.H. Revkin, D.E. Grobbee, W.A. Riley, C.L. Shear, W.T. Duggan, M.L. Bots RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
6. A. Tall, L. Yvan-Charvet, and N. Wang The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 2007 257 260
7. R.S. Vasan, M.J. Pencina, S.J. Robins, J.P. Zachariah, G. Kaur, R.B. D'Agostino, and J.M. Ordovas Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community Circulation 120 2009 2414 2420
8. A. Ritsch, H. Scharnagl, P. Eller, I. Tancevski, K. Duwensee, E. Demetz, A. Sandhofer, B.O. Boehm, B.R. Winkelmann, J.R. Patsch, and W. Mrz Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study Circulation 121 2010 366 374
9. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer, A.M. Skene Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
10. P.M. Ridker, C.P. Cannon, D. Morrow, N. Rifai, L.M. Rose, C.H. McCabe, M.A. Pfeffer, E. Braunwald Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI22) Investigators C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
11. C. Ahnadi, F. Berthezne, and G. Ponsin Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to very low and low density lipoproteins in normolipidemic subjects Atherosclerosis 99 1993 219 228
12. A. Inazu, J. Koizumi, K. Kajinami, T. Kiyohar, K. Chichibu, and H. Mabuchi Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and Probucol in patients with primary hypercholesterolemia and xanthoma Atherosclerosis 145 1999 405 413
13. F.V. van Venrooij, R.P. Stolk, J.D. Banga, T.P. Sijmonsma, A. van Tol, D.W. Erkelens, G.M. Dallinga-Thie DALI Study Group Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes Diabetes Care 26 2003 1216 1223
14. S.M. Boekholdt, J.A. Kuivenhoven, N.J. Wareham, R.J. Peters, J.W. Jukema, R. Luben, S.A. Bingham, N.E. Day, J.J. Kastelein, and K.T. Khaw Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study Circulation 110 2004 1418 1423
15. P. Marschang, A. Sandhofer, A. Ritsch, I. Fier, E. Kvas, and J.R. Patsch Plasma cholesteryl transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin J Intern Med 260 2006 151 159
16. A.H. Klerkx, G.J. de Grooth, A.H. Zwinderman, J.W. Jukema, J.A. Kuivenhoven, and J.J. Kastelein Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS) Eur J Clin Invest 34 2004 21 28
17. F. Tat, G.L. Vega, A.R. Tall, and S.M. Grundy Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia Arterioscler Thromb Vasc Biol 15 1995 112 120
18. M. Harangi, H.Z. Mirdamadi, I. Seres, F. Sztanek, M. Molnr, A. Kassai, Z. Derdk, L. Illys, and G. Paragh Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity Transl Res 153 2009 190 198
19. S.E. Borggreve, H.L. Hillege, G.M. Dallinga-Thie, P.E. de Jong, B.H. Wolffenbuttel, D.E. Grobbee, A. van Tol, R.P. Dullaart PREVEND Study Group High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides Eur Heart J 28 2007 1012 1018
20. M. Zeller, D. Masson, M. Farnier, L. Lorgis, V. Deckert, J.P. Pais de Barros, C. Desrumaux, P. Sicard, J. Grober, D. Blache, P. Gambert, L. Rochette, Y. Cottin, and L. Lagrost High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction J Am Coll Cardiol 50 2007 1948 1955
21. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr, N.J. Stone National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
22. J.J. Regieli, J.W. Jukema, D.E. Grobbee, J.J. Kastelein, J.A. Kuivenhoven, A.H. Zwinderman, Y. van der Graaf, M.L. Bots, and P.A. Doevendans CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur Heart J 29 2008 2792 2799
23. A. Thompson, E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R.P. Dullaart, B. Keavney, Z. Ye, and J. Danesh Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk JAMA 299 2008 2777 2788
24. C. Schwartz, J. VandenBroek, and P. Cooper Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans J Lipid Res 45 2004 1594 1607
25. H. Tanigawa, J.T. Billheimer, J. Tohyama, Y. Zhang, G. Rothblat, and D.J. Rader Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport Circulation 116 2007 1267 1273
26. A. Endo The discovery and development of HMG-CoA Reductase Inhibitors J Lipid Res 33 1992 1569 1582
27. R. McPherson, C.J. Mann, A.R. Tall, M. Hogue, L. Martin, R.W. Milne, and Y.L. Marcel Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia Relation to cholesteryl ester transfer protein activity and other lipoprotein variables Arterioscler Thromb 11 1991 797 804